Oncology Institute Inc. (TOIIW)
Oncology Institute Statistics
Share Statistics
Oncology Institute has 75.75M shares outstanding. The number of shares has increased by -87% in one year.
| Shares Outstanding | 75.75M |
| Shares Change (YoY) | -87% |
| Shares Change (QoQ) | 0.26% |
| Owned by Institutions (%) | 0% |
| Shares Floating | 32.51M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 2.6K, so 0% of the outstanding shares have been sold short.
| Short Interest | 2.6K |
| Short % of Shares Out | 0% |
| Short % of Float | 0.01% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -358.61 and the forward PE ratio is null. Oncology Institute's PEG ratio is 3.59.
| PE Ratio | -358.61 |
| Forward PE | n/a |
| PS Ratio | 58.94 |
| Forward PS | null |
| PB Ratio | 6460.99 |
| P/FCF Ratio | -764.62 |
| PEG Ratio | 3.59 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Oncology Institute.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.15, with a Debt / Equity ratio of 8.36.
| Current Ratio | 2.15 |
| Quick Ratio | 1.96 |
| Debt / Equity | 8.36 |
| Debt / EBITDA | -0.59 |
| Debt / FCF | -0.99 |
| Interest Coverage | -8.02 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $476.86K |
| Profits Per Employee | $-78.38K |
| Employee Count | 825 |
| Asset Turnover | 2.28 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.24, so Oncology Institute's price volatility has been higher than the market average.
| Beta | 0.24 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.03 |
| 200-Day Moving Average | 0.04 |
| Relative Strength Index (RSI) | 51.35 |
| Average Volume (20 Days) | - |
Income Statement
In the last 12 months, Oncology Institute had revenue of 393.41M and earned -64.66M in profits. Earnings per share was 0.
| Revenue | 393.41M |
| Gross Profit | 393.41M |
| Operating Income | -60.12M |
| Net Income | -64.66M |
| EBITDA | -50.88M |
| EBIT | -57.17M |
| Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has 49.67M in cash and 30.02M in debt, giving a net cash position of 19.65M.
| Cash & Cash Equivalents | 49.67M |
| Total Debt | 30.02M |
| Net Cash | 19.65M |
| Retained Earnings | -210.81M |
| Total Assets | 172.72M |
| Working Capital | 60.2M |
Cash Flow
In the last 12 months, operating cash flow was -26.54M and capital expenditures -3.79M, giving a free cash flow of -30.33M.
| Operating Cash Flow | -26.54M |
| Capital Expenditures | -3.79M |
| Free Cash Flow | -30.33M |
| FCF Per Share | 0 |
Margins
Gross margin is 100%, with operating and profit margins of -15.28% and -16.44%.
| Gross Margin | 100% |
| Operating Margin | -15.28% |
| Pretax Margin | -16.44% |
| Profit Margin | -16.44% |
| EBITDA Margin | -12.93% |
| EBIT Margin | -15.28% |
| FCF Margin | -7.71% |
Dividends & Yields
TOIIW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for TOIIW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -0.1 |
| Piotroski F-Score | 3 |